DRL had entered into a confidential settlement agreement with Celgene for its abbreviated new drug submissions for a generic version of Revlimid capsules, used for treatment of multiple myeloma (cancer), pending approval before Health Canada. It has now received Rs 346 crore from Celgene, bumping up profits.